Evommune scraps eczema drug after mid-stage trial misses main goal
Evommune said it will not advance its experimental skin disease drug after failing to meet the main goal in a mid-stage trial, sending shares down 24% in aftermarket trading.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.